Last reviewed · How we verify
Eylea
At a glance
| Generic name | Eylea |
|---|---|
| Also known as | aflibercept, Aflibercept, Eylea is the brand name., Aflibercept is the generic name., The DIN is 02415992. |
| Sponsor | Texas Retina Associates |
| Target | Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Branch retinal vein occlusion with macular edema
- Central retinal vein occlusion with macular edema
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Metastasis from malignant tumor of colon
- Neovascular glaucoma
- Retinopathy of prematurity
Common side effects
- Cataract
- Vision blurred
- Intraocular pressure increased
- Conjunctival hemorrhage
- Ocular discomfort/eye pain/eye irritation
- Vitreous floaters
- Vitreous detachment
- Corneal epithelium defect
- Retinal hemorrhage
- Lacrimation increased
- Eyelid edema
- Hypersensitivity (rash, urticaria, pruritus)
Serious adverse events
- Endophthalmitis
- Retinal detachments
- Retinal vasculitis with or without occlusion
- Occlusive retinal vasculitis
- Thromboembolic events
- Scleritis
- Hypersensitivity
Key clinical trials
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (PHASE1)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (PHASE3)
- Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (PHASE3)
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
- An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eylea CI brief — competitive landscape report
- Eylea updates RSS · CI watch RSS
- Texas Retina Associates portfolio CI